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Epigenetics of Circadian Rhythm 




Circadian rhythm influences the regulation of homeostasis and physiological 
processes, and its disruption could lead to metabolic disorders and cardiovascular 
diseases (CVD). CVDs are still the dominant cause of death worldwide, which are 
related to numerous environmental and hereditary risk factors. Environmental 
and hereditary factors can clarify a small fraction of the CVD risk discrepancy. 
Epigenomics is a very bright strategy that will complement the knowledge of the 
genetic basis of CVDs. Epigenetic mechanisms allow cells to reply promptly to envi-
ronmental changes and include DNA methylation, histone modification, and non-
coding RNA alterations. According to research data, the circadian rhythm regulates 
many epigenetic regulators. The challenge is to understand how epigenetic events 
happen rhythmically in tissues that are involved in the development of CVDs. 
Epigenetic events are possibly reversible through their interface with environmental 
and nutritional factors, allowing innovative preventive and therapeutic strategies in 
cardiovascular diseases.
Keywords: circadian rhythm, cardiovascular disease, epigenetics, DNA methylation, 
histone modification, microRNA
1. Introduction
The word epigenetics comes from the Greek word ‘epi’ that means above; that 
is, hereditary variations in phenotype that do exclude alterations in the nucleo-
tide sequence in DNA [1]. Epigenetic mechanisms involve DNA methylation, 
post-translational histone modifications, and noncoding RNAs (ncRNAs) [1]. 
Many studies focus on the epigenetic mechanisms of various diseases. Epigenetic 
processes are essential for the healthy growth and development of an organism [1]. 
Epigenetic mechanisms are implicated in the expression of circadian genes in the 
suprachiasmatic nucleus (SCN) neurons and peripheral tissues [2]. The accumula-
tion of lifestyle and age-related epigenetic changes could result in the development 
of metabolic disorders and atherosclerosis [2].
The influence of epigenetic changes on the cardiovascular system is an essential 
link between genotype to phenotype diversity [3]. Epigenetic changes are potentially 
reversible and may be affected by environmental factors, nutrition, as well as gene-
environment interactions. Identifying and understanding epigenetic factors represent 




The circadian clock is a preserved system that allows organisms to adapt to 
frequent daily variations, such as the day and night and food availability [4]. This 
center clock receives signals from the environment and coordinates the daily activ-
ity of peripheral clocks found in almost all tissues [4]. The molecular clock is vital 
in maintaining metabolic and physiological homeostasis [5]. The circadian clock 
is linked to cellular metabolism so that dysregulation of the circadian rhythm can 
contribute to various pathological conditions such as diabetes, obesity, metabolic 
syndrome, inflammation, sleep disorders, and CVDs [5–8].
Genome-wide studies show that 10–15% of all transcripts have a circadian 
pattern in different tissues involved in the control of metabolism, such as the 
cardiovascular function [4, 6, 8, 9]. The onset of ischemic cardiopathy is irregularly 
distributed during the day [1, 10, 11]. A chronobiological strategy to heart disease 
may present new possibilities to enhance drug development to improve therapeutic 
outcomes [1]. Genetic evidence supports the function of circadian rhythm in the 
adjustment of metabolism.
1.2 Cardiovascular diseases
Cardiovascular diseases are complex and diverse. They include hypertension, 
coronary artery disease, heart failure, and stroke and are a main worldwide reason 
for morbidity and death in advanced economies and carry a substantial economic 
burden [1, 3, 12–15]. CVDs are associated with a variety of hereditary and variable 
risk factors, but environmental and genetic impacts may explain a smaller fraction 
of CVD risk variability [1, 12]. Studies showed that there is a wide range between 40 
and 80% of the genetic contribution to the onset of cardiovascular disease [16].
The complex pathogenesis of CVD is due to the abundance of genetic and envi-
ronmental factors, of which epigenetic changes are a significant factor [3]. Several 
risk factors of CVD, like diet, smoking, stress, circadian rhythm, and pollution, are 
related to epigenetic modifications [1]. Disorders such as hypertension, diabetes, 
and obesity are often utilized to recognize and cure people at increased CVDs risk 
[1]. Epigenetic modifications are associated with the processes involved in the CVD 
in humans or directly affect the gene expression involved in a major cardiac com-
plication, myocardial infarction (MI). Hypertension is one of the leading causes of 
CVDs [3], while insulin resistance is one of the most significant precursors of type 2 
diabetes and associated cardiometabolic conditions [17].
Changes in the style of living and diet could decrease the risk of CVDs [14]. 
Epigenetic factors indicate there is interindividual variability from birth. It can be 
stable over the life span and is considered to be an initiator of early programming 
for adult-onset diseases [12, 18]. The understanding of epigenetics in the onset of 
CVDs may provide a new perspective on diseases [14].
1.3 Epigenetics
Epigenetics studies heritable variations in gene expression that exclude any 
change in the DNA sequence [16, 19]. Epigenetic changes include modifications of 
the DNA base, post-translational histone modifications, and ncRNA mechanisms 
that run in the nucleus [16, 20]. The epigenome moves the genome from a transcrip-
tionally active to a transcriptionally inactive state [4, 21]. Epimutation transmis-
sions occur throughout the life of the individual [2]. The rate of epigenetic variation 
is higher than that of genetic mutations because the formation of new inherited 
changes allows adjustment to a new environment [14, 16].
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The most studied epigenetic change is cytosine methylation. It is also a method 
for suppressing gene expression [22]. DNA methyltransferase (DNMT) enzymes 
perform DNA methylation. DNMTs bind the methyl group to the 5-site cytosine 
[16]. The methyl group most commonly binds to the cytosine at a CpG site. It is 
the fundamental and ubiquitous epigenetic mechanism [14]. The DNMT enzyme 
family, consisting of DNMT1, DNMT3a, and DNMT3b, methylates cytosine into 
5-methylcytosine [14]. Promoter methylation is usually connected with inhibition 
of transcription [14]. DNMT1 controls the mitotic inheritance of methylated DNA, 
while DNMT3a and DNMT3b are mainly in charge of de novo methylation [14]. The 
different epigenetic modification is DNA hydroxymethylation, including 5-hydroxy-
methylated cytosines [14]. Different nutritional and lifestyle factors can affect the 
methylation of particular CpG sites in gene promoters and into adulthood [22].
Nucleosomes are composed of histone proteins around which DNA is wound 
into chromatin [16]. Nucleosomes consist of eight histone proteins: two dimers 
of H2A/H2B and two dimers of H3/H4. Each histone has an adjustable amino-
acid tail [16]. Histones can change at more than 30 amino acid residues within 
amino-terminal tails [4]. Histone modifications include various processes such as 
acetylation, methylation, phosphorylation, sumoylation, and ubiquitination. It has 
a function in the organization of chromatin composition and gene expression by 
altering the intensity of chromatin condensation [1, 14, 23]. Histones are mostly 
acetylated on lysine (K) residues. Histone acetyltransferase (HAT) and histone 
deacetylase (HDAC) regulate histone acetylation [14]. Histone methyltransferase 
regulates histone methylation, while histone demethylase catalyzes demethylation. 
Transcription activation is usually associated with acetylation of lysine residues 
at histones 3 (H3) and 4 (H4). Depending on the location of the target lysines in 
the histone tail and the number of methyl groups added, methylation can either 
activate or inhibit gene expression [14, 24]. Histone phosphorylation is a marker 
of cell division and has a function in DNA repair, chromatin condensation during 
division, and regulation of gene expression [14, 25]. The addition of ubiquitin to 
lysine residues in histones is called ubiquitination and is implicated in DNA repair 
and control of transcription [14]. Sumoylation is a changeable post-translational 
adjustment using small ubiquitin-like proteins (SUMO) and has a crucial function 
in various mechanisms, such as transcription, and cell cycle progression [14, 26].
RNA-based epigenetic mechanisms include long noncoding RNAs (lncRNAs) 
and microRNAs (miRNAs) [14]. NcRNAs are functional RNAs that do not trans-
late into proteins and play an essential part in epigenetic regulation [14, 16]. The 
lncRNAs are extremely tissue-specific relative to protein-coding genes [16]. The 
miRNAs are short (20–22 nucleotides), single-stranded, evolutionarily-conserved 
ncRNAs that modulate the expression at the post-transcriptional level of more than 
50% of cellular genes [13, 14, 27].
Changes in the environment, including temperature, light, and nutritional habits, 
trigger reversible epigenomic modification that can influence numerous physiological 
processes [28]. Epigenome-wide association studies (EWAS) provide information 
about associations between epigenomic perturbations and traits associated with 
human diseases [29]. EWAS try to evaluate the environmental impact on genetic regu-
lation. The epigenetic variations could explain missing parts of heritability of chronic 
diseases that have not yet been determined by genome-wide association studies [29].
2. Molecular background of circadian rhythm
The primary clock genes show circadian expression in the SCN, and light is one 
of the key drivers that can reset the rhythm phases. There are several crucial proteins 
Cardiac Diseases
4
in SCN. Transcription activators are aryl hydrocarbon receptor nuclear translocator-
like (ARNTL or BMAL1) and circadian locomotor output cycle caps (CLOCK). 
Transcription inhibitors are period (PER) and cryptochrome (CRY) [30, 31]. Within 
24 h, the entire process of activation and inhibition of gene expression takes place 
[32, 33]. The circadian system controls gene expression through various mechanisms 
as a basis of global gene regulation. The first is via E-boxes (promoter and enhancer 
regulatory elements) of oscillator proteins such as CLOCK, ARNTL, and NPAS2 
(neuronal PAS domain protein 2). The second mechanism is using other oscillator 
proteins such as RORα (retinoic acid receptor-related orphan receptor) and REV-
ERBα (or NR1D1, orphan nuclear receptor) via REV-ERB/ROR response element 
(RRE), which are present in the promoters of specific clock-controlled genes (CCGs) 
(Figure 1). The third mechanism is the daily chromatin remodeling [2, 19, 34, 35].
The ARNTL-CLOCK heterodimers enhance CRY and PER expression, as well as 
the expression of additional CCGs. Phosphorylated CRY-PER heterodimers repress the 
action of ARNTL-CLOCK heterodimer. As a result, CRY and PER gene transcription is 
decreased during the day, while ubiquitin degradation reduces the CRY and PER protein 
levels. The PER2 has histone deacetylase activity and modified chromatin structure, 
followed by transcription termination [36–39]. The new cycle begins with the termina-
tion of the ARNTL-CLOCK repression during the day. Casein kinase 1 (CK1) regulates 
the quantity of CRY-PER heterodimers’ phosphorylation or degradation. CK1 controls 
protein activity via its phosphorylation [40]. An additional negative loop is REV-ERBα. 
It binds to the RRE of the ARNTL and CLOCK genes and inhibits their transcription. 
Overnight, REV-ERBα degrades, and RORα elevates the ARNTL gene transcription [2, 
32, 41]. ARNTL-CLOCK heterodimers increase transcription of the nuclear recep-
tors RORα and REV-ERBα and form an additional circadian rhythm loop [31, 42].
Nearly 10% of the transcripts show circadian rhythmicity [19]. Rhythmic expres-
sion of crucial metabolic genes is impaired due to clock gene mutations and lead 
to metabolic disorders [28]. Fasting glucose levels decrease, and insulin sensitivity 
Figure 1. 
Circadian rhythm gene regulation in cardiovascular diseases. ARNTL and CLOCK activate transcription 
of CRY and PER and nuclear receptors (REV-ERBα and RORα). CRY and PER heterodimerize and 
phosphorylate by casein kinases and translate into the nucleus where they prevent binding of the ARNTL-
CLOCK to the regulatory regions of target genes. In the second feedback loop, REV-ERBα prevents the 
transcription of ARNTL, while overnight the RORα activates transcription of ARNTL. ARNTL—aryl 
hydrocarbon receptor nuclear translocator-like, CLOCK—circadian locomotor output cycle kaput, CRY—
cryptochrome, PER—period, P—phosphate, RORα—retinoic-related orphan receptor alpha, Ub—ubiquitin.
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increases in overexpression of the CRY1 [28]. ARNTL deletion and CLOCK muta-
tion disturb lipid metabolism [28, 43]. REV-ERBα is involved in liver circadian lipid 
biosynthesis, and REV-ERBα and ARNTL manage adipocyte differentiation [28]. 
A primary regulator of bile acid synthesis is REV-ERBα, while the PER1 and PER2 
deletion upregulates bile acid biosynthesis and causes hepatic cholestasis [28].
Based on circadian rhythms in SCN neurons and peripheral cells, epigenetic 
mechanisms participate in the formation of circadian rhythms of gene expres-
sion [2]. One of the primary circadian genes, CLOCK, has the function of histone 
acetyltransferase. Chromatin remodeling is an essential underlying mechanism of 
the clock rhythm and reveals an association between cellular physiology and histone 
acetylation [2]. ARNTL-CLOCK heterodimer or ARNTL-NPAS2 complex mobilizes 
HATs and HDACs [28, 44]. To maintain metabolic homeostasis and avoid metabolic 
disorders, the crosstalk between circadian rhythm and metabolism is necessary [28].
3. Epigenetic changes in circadian rhythm in cardiovascular diseases
Rapid adaptation of cells to environmental changes is facilitated by epigenetic 
mechanisms that also offer a link between genes and the environment [1]. The phe-
notypic variations observed in humans are more significant than genotype variations 
alone, and changes in epigenetic gene modification explain them [1, 45]. CVDs, such 
as atherosclerosis, cardiac hypertrophy, myocardial infarction, and heart failure, are 
associated with epigenetic mechanisms ranging from DNA methylation, histone modi-
fication, to ncRNAs [13]. An essential way of developing CVD early in life involves 
epigenetic changes [12]. The underlying mechanism providing the link between the 
early life environment and the subsequent CVD risk is epigenetic modifications [12].
The association of methylation with specific genes may be useful in assessing the 
risk of a disease or in monitoring the response to a particular treatment [14]. In 
the process of DNA methylation, homocysteine, an amino acid that does not enter 
into protein composition, is essential [46]. The lack of folate in the diet leads to an 
increase in plasma homocysteine, which contributes to the rise of S-adenosyl homo-
cysteine. It represses transmethylation reactions and decreases methylation all over 
the epigenome [1, 46]. In atherogenesis are included homocysteine-induced changes 
in DNA methylation in smooth muscle vascular cells [1, 47, 48]. Endothelial dys-
function and different aspects of CVD are epigenetically associated with folic acid 
deficiency [16]. Genomic DNA is hypomethylated in human atherosclerotic lesions 
[1, 2, 12]. Inflammatory processes involved in the development of atherosclerotic 
plaques are associated with hypermethylation [1, 49]. There are rhythmic changes 
in global DNA methylation in human blood, and there is an increased level at night 
[35]. Changes in circadian rhythm genes methylation were observed in aging mice, 
but are tissue-dependent [35, 50]. For example, in the stomach of older mice, the 
methylation of the PER1 promoter decreased, while the methylation of the ARNTL, 
CRY1, and NPAS2 promoters in the spleen was increased [35]. Sleep disorders affect 
circadian rhythm gene methylation, especially ARNTL, CRY1, and PER1 [35, 51]. 
Temporary epigenetic changes linked with rhythmic gene expression lead to circa-
dian epiphenotypes [2]. Based on this, it can be concluded that DNA methylation 
may be reversed by conventional drugs, independent of DNA replication [2].
The histone code is involved in many aspects of cardiovascular physiology, from 
endothelial cell responses to hypoxia to recovery from MI [16]. CLOCK has enzymatic 
properties of histone acetyltransferase (HAT). It performs acetylation at Lys537 of H3 
histone and ARNTL, which is necessary for circadian rhythm [1, 9]. CLOCK works in 
collaboration with other HATs to maintain circadian rhythm in the acetylation state of 
histones at CCG promoters [6]. HDAC activity has an essential function in defining 
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the intensity of myocardial ischemia, especially after MI [16]. Inhibition of HDAC can 
promote angiogenesis and reduce myocardial damage after MI [16], such as valproic 
acid (VPA), which is an HDAC inhibitor [2]. Histone deacetylases, SIRT1 (sirtuin 1), 
and SIRT6 participate in the histone modification, thus controlling gene expression 
[35] and providing a molecular connection among metabolism and circadian rhythm 
[6]. SIRT1 deacetylates regulatory proteins and acts as a rhythm-promoting agent in 
circadian oscillators [35]. SIRT1 has a unique role in central and peripheral circadian 
rhythms [35]. The purpose of histone phosphorylation in CVDs is minimal [14], while 
SUMO proteins influence the activity of several essential factors that are important 
for cardiac development [14]. There are connections between circadian rhythm 
regulators, chromatin modifications, and cellular metabolism [1, 52].
Numerous lncRNAs have essential regulatory functions in various CVDs [14]. 
The miRNAs regulate cholesterol metabolism, oxidative stress, and endothelial 
dysfunction, diverse cellular processes involved in atherosclerosis [14]. MiRNAs 
may be relevant regulators of circadian rhythm [1]. Circulating miRNA-145 and 
miRNA-126 are decreased in patients with coronary artery disease, while miRNA-1, 
miRNA-499, and miRNA-133b are increased during acute myocardial infarction 
[13]. All those miRNAs can be biomarkers of CVD.
Circadian rhythms combine metabolic and environmental signals and alter 
gene expression when adapting the organism to particular circumstances [6]. Many 
epigenetic regulators in some tissues are controlled in a circadian fashion [19, 53]. The 
challenge is to determine whether epigenetic variations happen in a rhythmic pattern 
in tissues included in the CVD development [12, 19]. Epigenetics can contribute to 
enhancing CVD therapies and finding new markers for CVD  screening [16, 54].
4. DNA methylation and CVDs
DNA methylation is a durable, relatively constant epigenetic change. It involves 
the covalent attachment of a methyl group to the cytosine [3, 55]. The primary role 
of DNA methylation is to regulate gene expression by altering the availability of 
DNA to the transcription factors [3, 13].
DNA methylation links the steady genome and the changing environment. It 
is an instrument through which environmental changes influence metabolism [7]. 
Disruption of DNA methylation has been associated with different metabolic diseases 
such as diabetes [56], obesity, and insulin resistance [57]. Furthermore, the epigen-
etic mechanisms control circadian rhythm, and circadian disturbance leads to DNA 
methylation changes of the clock genes [7, 51, 58]. Adiposity, metabolic syndrome, 
and weight loss are linked to DNA methylation changes of the ARNTL, CLOCK, and 
PER2 gene promoters [7]. It indicates the significance of determining the impact of 
DNA methylation in epigenetic studies in complex human disorders [7].
DNA methylation is cell- or tissue-specific, but epimutations are not restricted 
to the affected tissue and may also be observed in peripheral blood [7]. Compared 
to other genes, the regulatory regions of circadian rhythm genes are plentiful in 
CpG sites [59, 60]. Patients with coronary artery disease have altered methylation 
patterns relative to controls [1, 61, 62]. All mentioned supports the assumption that 
epigenetic variations are associated with an increased CVD risk [1].
Epigenetic alterations of circadian genes are related to obesity and metabolic 
disorders [17, 63]. A positive association was found between the alteration of 
the ARNTL gene methylation and weight loss, and its activity is included in the 
control of adipogenesis and lipid metabolism [63]. The long-term shiftwork, 
associated with obesity and metabolic syndrome risk, induces hypomethylation 
of the CLOCK gene promoter [22]. CLOCK gene SNPs are associated with a 
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predisposition to metabolic syndrome [22, 64]. Long-term shift work, obesity, 
and metabolic syndrome are associated with CRY2 hypermethylation in peripheral 
blood [22]. Genetic variants of the human PER2 gene are related to abdominal 
obesity and CVDs [22, 65]. The methylation status of CpG sites in the PER2 gene is 
associated with obesity, metabolic syndrome, and weight loss [7, 22].
Global hypomethylation of DNA is present in atherosclerotic lesions [3, 66]. The 
severity of atherosclerotic lesions correlates with DNA methylation [3, 14, 67, 68]. 
There are notable variations in DNA methylation after an MI event [69, 70]. DNA 
methylation status in blood samples is related to CVD [71, 72].
Environmental and behavioral factors, such as inflammation, smoking, physical 
activity, or stress, can alter the epigenome [63, 73]. Elevated gene expression in the 
inflammatory pathway is associated with decreased gene methylation [46]. DNA 
methylation relies on the accessibility of methyl groups obtained from methionine, 
and the existence of certain nutrients in the food influences epigenetic changes 
with possible cardiovascular outcomes [46]. Although methylation changes are 
related to healthy aging, they could be in the background of the development of 
some diseases, such as CVD [46, 74]. Reduction in global DNA methylation occurs 
throughout the human lifespan [46].
5. Histone modification and CVDs
Post-translational modifications occur at amino acid residues in the amino-termi-
nal regions of histone and cover histone acetylation, methylation, phosphorylation, 
sumoylation, and ubiquitination. It controls chromatin remodeling and gene expres-
sion [3, 23]. Histone acetylation is a sign of transcription activation [75], while histone 
methylation can both stimulate and inhibit transcription [28, 75]. Post-translational 
histone modifications control genes coding clock proteins [46, 75].  Epigenetic 
 irregularities are related to different disorders, including  atherosclerosis [4, 76].
Histone modifications occur at the CCG promoters in a circadian fashion [4, 44, 
77, 78]. The core clock protein, CLOCK, has HAT activity. It revealed the molecular 
association among epigenetic mechanisms and circadian rhythm [4, 19, 59, 79]. 
CLOCK acetylates ARNTL, which facilitates CRY-dependent repression [19, 28], and 
interaction of CRY1 with the ARNTL-CLOCK heterodimer [9]. CLOCK and NPAS2 
attract different HATs to the promoter of the PER1 in vascular tissues [59, 78]. The 
rhythmic binding of ARNTL and CLOCK transcriptional activators directly influences 
the acetylation of specific histone lysine residues near the DNA-binding site without 
the involvement of additional HAT enzymes [59]. CLOCK acetylates additional non-
histone proteins that have crucial roles in the regulation of different cellular events [4].
SIRT1 is an NAD + -dependent histone deacetylase [4, 59, 80]. It is needed for 
rhythmic transcription of some clock genes, such as ARNTL, CRY1, and PER2 
[80, 81]. STIR1 represents the molecular connection between metabolic processes, 
chromatin remodeling, and circadian physiology [4]. SIRT1 plays a crucial role in 
metabolism. It deacetylates some proteins of the metabolic pathways and regulates 
gene expression by histone deacetylation [75]. SIRT1 expression levels are nearly 
constant over 24 h, just like relatively constant CLOCK gene expression levels*** 
[4, 82–85]. The HAT function of CLOCK is balanced by SIRT1, which deacetylates 
H3 and ARNTL, and PER2 [79, 83, 86]. SIRT1 binds to ARNTL-CLOCK within a 
chromatin complex that, in a circadian fashion, binds to CCG promoters [4, 87]. 
ARNTL and PER2 are SIRT1 targets [4]. SIRT1 associates with ARNTL-CLOCK 
heterodimers and improves the deacetylation and degradation of PER2 [86]. SIRT1 
deacetylates clock proteins in a circadian fashion [4]. HDAC3 is a deacetylase that 
modulates histone acetylation of circadian genes, especially those included in lipid 
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metabolism, such as REV-ERBα [88–92]. Mutations of circadian rhythm proteins 
that can either modify histones (such as CLOCK) or link to histone modifiers (such 
as ARNTL, PER2, and REV-ERBα) are related to metabolic syndrome [75, 79]. 
Endogenous SIRT1 plays a crucial role in mediating cell death/survival processes 
and is involved in the pathogenesis of the CVDs [28, 93]. The ARNTL sumoylation 
plays an essential role in ARNTL accumulation and circadian rhythmicity [86].
Histone modifications, and particularly HDACs, have a significant role in 
the control of vascular homeostasis. Dysregulation of HDAC could lead to the 
formation of atherosclerotic lesions [14, 94]. In human carotid arteries, histone 
methylation and acetylation present recognizable patterns depending on the 
seriousness of the plaque [46]. Inhibition of HDACs leads to reduced inflammation 
and atherogenesis [46, 95]. In animal studies, HDAC inhibitors reduce the size of 
MI and ischemia-reperfusion injury after revascularization [46, 96]. The inhibition 
of HDAC may improve myocardial recovery and block post-infarction remodeling 
[46]. Fibrosis after MI was reduced by valproic acid, an HDAC inhibitor [14, 97].
6. MicroRNAs and CVDs
MicroRNAs (miRNAs) are small noncoding RNA molecules that repress the 
expression of target messenger RNAs [1, 3, 5, 98]. MicroRNA dysregulation is 
associated with cardiovascular diseases, lipid metabolism, endothelial function, 
ventricular hypertrophy, and post-infarction dysrhythmias [1, 5].
Oscillating microRNAs, based on external triggers, could affect the expression 
of target genes in a circadian fashion independently of clock genes [5, 99]. In plasma 
and serum of CVD patients are observed decreased levels of numerous miRNAs, 
such as miRNA-126, miRNA-17, miRNA-145, miRNA-92a, and miRNA-155 [3].
MiRNAs control the development of atherosclerosis through their action on 
endothelial function, plaque progression and rupture, and blood vessel develop-
ment [46]. MiRNA-126 expressed by endothelial cells serves as an adverse adjuster 
of vascular inflammation, while miRNA-33 plays a vital role in inhibiting the criti-
cal genes implicated in cellular cholesterol export [14, 100]. Some miRNAs target 
DNMTs and thus regulate the level of DNA methylation in atherosclerotic lesions 
[14]. MiRNA-148 changes HDL and LDL cholesterol levels in murine models and 
thus has a vital function in lipid metabolism [46, 101, 102].
MiRNA-24, 29a, and 30a influence the circadian rhythm by regulating the 
stability and translation of PER1 and PER2 mRNAs [5]. The ARNTL-CLOCK 
heterodimer controls miRNA-142–3p and, in turn, can target ARNTL [5, 103, 104]. 
MiRNA-21 is a PER2-dependent miRNA and mediates PER2-obtained cardioprotec-
tion [5, 105]. Through cellular stress, PER2-dependent miRNA-21 controls cellular 
glycolysis. Myocardial ischemia causes activation of pathways aimed at increasing 
the efficiency of myocardial oxygen [5, 106]. Suppression of miRNA-21 reduces the 
fibrotic response and enhances cardiac activity [5].
A valuable sign of myocardial cell death is the plasma levels of miRNA-208 [3, 
107]. MiRNAs have a function in remodeling after MI, a mechanism closely associ-
ated with the expansion of tissue fibrosis [14]. A more sensitive biomarker of acute 
non-STEM MI is miRNA-499 than cardiac troponin T [46].
MicroRNAs could potentially become new modulators of circadian rhythms 
and could have a positive effect on cardiovascular physiology [5]. MiRNAs regulate 
about 60% of all human genes [46]. Therapeutic strategies should target specific 
microRNAs and thus reduce their capacity to inhibit circadian rhythm components 
or circadian rhythm output genes [5, 108–112]. Administration of microRNAs in a 
circadian-dependent fashion could serve to adapt the impaired circadian system, 
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advance metabolism by enhancing efficient oxygen pathways, and thereby promote 
cardioprotection from ischemia [5].
7. Conclusion
The epigenetic variations of an individual change throughout a lifetime and 
epigenome profiles, instead of genotypes, are reflected in phenotypes in epigenetic 
epidemiological studies. Therefore, epigenetic modifications are the reason or a 
result of a pathological condition. Understanding the epigenetic contribution to 
CVD pathology may help to develop new treatments and diagnostic approaches. 
Epigenetic biomarkers might be very useful in treatment monitoring and predicting 
disease outcome. Epigenetic events can potentially be reversibly altered depending 
on environmental and nutritional factors. Understanding epigenetic mechanisms 
may identify valuable, novel biomarkers for disease.
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